ALK and non-small cell lung carcinoma: Although these studies have clearly demonstrated the superior potency of lorlatinib to previous ALK inhibitors in both inhibitor-naïve and -resistant NB, acquired resistance to lorlatinib has been reported in the context of ALK fusion-positive NSCLC [106].